ClinicaliQ Trial Snapshot
- A Study to Evaluate the Efficacy and Safety of Rozanolixizumab in Adult Participants With Myelin Oligodendrocyte Glycoprotein (MOG) Antibody-associated Disease (MOGAD) — Active Not Recruiting • Phase III • NCT05063162.
- A trial testing whether rozanolixizumab safely and effectively treats adults with MOG antibody-associated nerve inflammation.
Verify eligibility, endpoints and current status on the original ClinicalTrials.gov registry before acting on this summary.
Use This Page For
- Quick orientation before opening the registry record.
- Checking recruitment status, phase and sponsor at a glance.
- Connecting this trial to nearby guidelines, Drug Science and education.
What This Trial Is Studying
The purpose of the study is to evalute the efficacy, safety and tolerability of rozanolixizumab for treatment of adult participants with myelin oligodendrocyte glycoprotein (MOG) antibody-associated disease (MOGAD). Conditions: Myelin Oligodendrocyte Glycoprotein Antibody-associated Disease (MOGAD) Interventions: Rozanolixizumab, Placebo Lead Sponsor: UCB Biopharma SRL Planned Enrollment: 113 participants